Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
3.030
-0.140 (-4.42%)
At close: Aug 14, 2026, 4:00 PM EDT
3.103
+0.073 (2.42%)
After-hours: Aug 14, 2026, 7:47 PM EDT
Myriad Genetics Revenue
Myriad Genetics had revenue of $190.70M in the quarter ending June 30, 2026, a decrease of -10.51%. This brings the company's revenue in the last twelve months to $806.60M, down -3.16% year-over-year. In the year 2025, Myriad Genetics had annual revenue of $824.50M, down -1.56%.
Revenue (ttm)
$806.60M
Revenue Growth
-3.16%
P/S Ratio
0.36
Revenue / Employee
$298,741
Employees
2,700
Market Cap
289.82M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 824.50M | -13.10M | -1.56% |
| Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
| Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
| Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
| Dec 31, 2021 | 690.60M | 133.50M | 23.96% |
| Dec 31, 2020 | 557.10M | -81.50M | -12.76% |
| Jun 30, 2020 | 638.60M | -212.50M | -24.97% |
| Jun 30, 2019 | 851.10M | 107.40M | 14.44% |
| Jun 30, 2018 | 743.70M | 15.00M | 2.06% |
| Jun 30, 2017 | 728.70M | -11.80M | -1.59% |
| Jun 30, 2016 | 740.50M | 17.40M | 2.41% |
| Jun 30, 2015 | 723.10M | -55.10M | -7.08% |
| Jun 30, 2014 | 778.20M | 165.00M | 26.91% |
| Jun 30, 2013 | 613.20M | 117.20M | 23.63% |
| Jun 30, 2012 | 496.01M | 93.92M | 23.36% |
| Jun 30, 2011 | 402.08M | 39.44M | 10.87% |
| Jun 30, 2010 | 362.65M | 36.12M | 11.06% |
| Jun 30, 2009 | 326.53M | 103.67M | 46.52% |
| Jun 30, 2008 | 222.86M | 77.57M | 53.39% |
| Jun 30, 2007 | 145.29M | 31.01M | 27.13% |
| Jun 30, 2006 | 114.28M | 31.87M | 38.68% |
| Jun 30, 2005 | 82.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| NeoGenomics | 766.30M |
| OPKO Health | 587.90M |
| Castle Biosciences | 357.28M |
| Fulgent Genetics | 323.93M |
| Biodesix | 102.94M |
| Burning Rock Biotech | 74.58M |
| Exagen | 71.12M |
| Personalis | 69.67M |
MYGN News
- 6 days ago - MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law - Business Wire
- 10 days ago - Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewsWire
- 12 days ago - Myriad Genetics price target lowered to $3 from $5.50 at Wells Fargo - TheFly
- 12 days ago - Myriad Genetics price target lowered to $3.20 from $4 at BofA - TheFly
- 14 days ago - Myriad Genetics price target lowered to $4 from $6 at TD Cowen - TheFly
- 15 days ago - Myriad Genetics cuts FY26 revenue view to $770M-$790M from $860M-$880M - TheFly
- 15 days ago - Myriad Genetics reports Q2 EPS (25c), consensus (6c) - TheFly
- 15 days ago - Myriad Genetics Earnings Call Transcript: Q2 2026 - Transcripts